KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $19.0 million.

  • Supernus Pharmaceuticals' Cost of Revenue rose 785.99% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.7 million, marking a year-over-year increase of 870.44%. This contributed to the annual value of $77.9 million for FY2024, which is 701.01% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Cost of Revenue of $19.0 million as of Q3 2025, which was up 785.99% from $16.8 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Cost of Revenue ranged from a high of $26.1 million in Q4 2024 and a low of $15.0 million during Q1 2021
  • Over the past 5 years, Supernus Pharmaceuticals' median Cost of Revenue value was $19.0 million (recorded in 2025), while the average stood at $19.8 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Cost of Revenue soared by 26016.38% in 2021, and later tumbled by 3048.17% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Cost of Revenue (Quarter) stood at $17.0 million in 2021, then soared by 35.07% to $23.0 million in 2022, then dropped by 14.49% to $19.6 million in 2023, then skyrocketed by 32.97% to $26.1 million in 2024, then fell by 27.33% to $19.0 million in 2025.
  • Its last three reported values are $19.0 million in Q3 2025, $16.8 million for Q2 2025, and $15.8 million during Q1 2025.